ATP7A and breast carcinoma: Herein, we describe how ATP7A specifically contributes to cisplatin resistance in breast cancer, and how combining cisplatin and ammonium tetrathiomolybdate (TM), which degrades ATP7A, to sensitizes breast tumor cells to cisplatin.